Sundern Sauerland

This research aims to assess how satisfied people with Multiple Sclerosis (MS) are after receiving subcutaneous (under the skin) injections of ocrelizumab over a period of 12 months. The study focuses on participants diagnosed with relapsing-remitting MS (RMS) or primary progressive MS (PPMS) according to 2017 McDonald criteria, who are starting ocrelizumab treatment for the first time. The main goal is to understand participant satisfaction using a special questionnaire designed for subcutaneous therapy administration. Participants will receive ocrelizumab as an injection under the skin, with the exact dosing and schedule determined by their treating physician following local medical guidelines. This observational study does not change standard care but monitors patients throughout their treatment with ocrelizumab. During the study, participants will complete the Therapy Administration Satisfaction Questionnaire for subcutaneous treatment after 12 months to measure their satisfaction. Researchers will also observe and record any relevant clinical information. The total study duration for each participant is 12 months, during which their experience and outcomes with ocrelizumab are carefully tracked.

The trial investigates the use of sublingual apomorphine (SL-APO) for treating OFF episodes in patients with Parkinson's disease. It aims to gather real-world data on how SL-APO is used and adjusted, focusing on determining individual doses after initial dose adjustments. The study seeks to understand how these dosing practices affect patient satisfaction, treatment adherence, and the balance between effectiveness and safety, potentially helping to improve dosing strategies. Participants start treatment with a 10 mg dose of SL-APO taken during OFF episodes. If this dose is tolerated and provides an adequate motor response within 30 minutes, it becomes the maintenance dose. Otherwise, the dose is increased in 5 mg steps up to a maximum of 30 mg per dose and up to five doses per day, with at least 2 hours between doses. Dose adjustments and responses are monitored both in clinic and at home, with follow-up visits at 3 and 6 months. Patients keep diaries recording their dosing and response from the second dose until the end of the study. After consenting, patients undergo a baseline visit where the initial 10 mg dose is tested. Dose titration continues at home if needed, with follow-up calls or visits to confirm the optimal dose. Patients maintain diaries throughout titration and the maintenance phase, with daily entries for at least the first week and weekly entries thereafter. The study ends at 6 months, with investigators deciding if patients should continue the maintenance dose afterward. The primary outcome is identifying the most frequently used dose after dose adjustments within six months.